

Floor Map

15th EURETINA Congress,
Nice Acropolis Exhibition Floor Plan - MEDITERRANEE




What is TOPCON University?

A global learning platform providing high quality information, education and training through knowledge sharing and accreditation.




Deep Range Imaging Swept Source OCT

OCT Angiography is a novel and non-invasive imaging technique to visualize the microvascular network




Courtesy of Srinivas R. Sadda, M.D.,
Doheny Eye Institute, UCLA



Courtesy of Srinivas R. Sadda, M.D.,
Doheny Eye Institute, UCLA

PASCAL Endpoint Management

Redefining Laser
Therapy for Macular
Disease with PASCAL



New TOPCON Technology Users Group Meeting

Euretina 2015, Nice

Angio-OCT and En-face OCT
Retinal Imaging and Swept-Source OCT choroidal
imaging: changes in clinical management
based on imaging findings
Update on new laser technologies,
clinical experience

Date 18 Sep 2015
Meeting 18:30-20:30
Buffet 20:30-21:30

Meeting Room: Iris

Chairman

Paulo E. Stanga, MD

Professor of Ophthalmology & Retinal Regeneration
Consultant Ophthalmologist & Vitreoretinal Surgeon
Director, Manchester Vision Regeneration (MVR) Lab
University of Manchester, Manchester Royal Eye Hospital &
NIHR Wellcome Trust Manchester CRF Manchester, UK

Speakers

OCT Session

Max Akiba, PhD (Japan)
Francesco Bandello, MD (Italy)
Jose Maria Ruiz Moreno, MD (Spain)
Magdy Moussa, MD (Egypt)
Paulo Stanga, MD (UK)

PASCAL Session

Jan EE Keunen, MD (The Netherlands)
Pascale Massin, MD (France)

Keynote Lecture

Gregoire Cosendai, PhD (Switzerland)

Venue

Nice Acropolis
1 Esplanade Kennedy, 06300 Nice, France
France

This meeting is supported by TOPCON University.



Chairman



Paulo E. Stanga, MD

Professor of Ophthalmology & Retinal Regeneration
University of Manchester
Consultant Ophthalmologist & Vitreoretinal Surgeon
Manchester Royal Eye Hospital
Director, Manchester Vision Regeneration (MVR) Lab
at NIHR/Wellcome Trust Manchester CRF

Prof. Paulo E. Stanga is a Consultant Ophthalmologist and Vitreoretinal Surgeon for the Manchester Royal Eye Hospital and Professor of Ophthalmology and Retinal Regeneration for the University of Manchester. Previous appointments: Lecturer in Ophthalmology for the University of Liverpool, Vitreoretinal Fellow at the Royal Liverpool University Hospital, Medical Retina Fellow at Moorfields Eye Hospital and Retina Research Fellow, New York Hospital, Cornell University Medical College, New York, USA.

Prof. Stanga is Director of the Manchester Vision Regeneration (MVR) Lab at NIHR/Wellcome Trust Manchester CRF and its Retinal Clinical-Research Fellowship Program, MREH Lead for the Retinal Laser Service, MREH and University of Manchester Laser Safety Representative, President of the Ophthalmic Imaging Association and Member of the Scientific Committee of the Royal College of Ophthalmologists.

Since 1993, Prof. Stanga has worked in the development and application of new outpatient and surgical therapies and technologies. Current research interests are: vitreo-retinal imaging, pharmacological, surgical and laser treatment of proliferative diabetic retinopathy and macular oedema, laser-tissue interaction, development of vitrectomy equipment, electronic retinal implants for artificial vision and stem-cell therapy.

Prof. Stanga has set up and directs an independent Clinical Research Fellowship Program at the Manchester Royal Eye Hospital and MVR Lab. The MVR Lab research team focus on developing research and treatment strategies in Medical Retina and Vitreoretinal conditions using the most advanced diagnostic and treatment devices.

Prof. Stanga has received several international accolades, amongst others, the prestigious Achievement Award by American Academy of Ophthalmology (AAO) for his regular contributions to its Annual Meeting.

Prof. Stanga introduced, amongst others, OCT into the clinical setting in the UK in 1998, Pascal Laser into the EU in 2006 and pioneered Swept-Source OCT introducing it into the EU in 2012.

Prof. Stanga has successfully carried out the first ever implantation of an electronic retinal implant in Age-related Macular Degeneration, which has also resulted in the first ever person with integrated artificial (central) and natural (peripheral) vision.

Dear Colleague

We would like to invite you to join us for the 5th New TOPCON Technology Users Meeting at Euretina 2015.

We continue to see advances in Optical Coherence Tomography (OCT) imaging, and this is of significant benefit to us and the patients we manage clinically. The newly available technology not only facilitates diagnosis and monitoring, but also allows for new treatment strategies to become clinically feasible.

Swept-Source OCT (SS-OCT) has now arguably become the new "Gold Standard" for imaging the Cortical Vitreous and the Vitreoretinal Interface and the Choroid. This new technology, which has evolved from SD-OCT, has provided new insights into several vitreoretinal and choroidal conditions and modified the way we manage them clinically; e.g. choroidal thickening in inflammatory diseases. The clinical information newly available has brought a consequent reduction in the need of invasive tests and the added benefit of a more objective monitoring of response to treatment.

Angio-OCT is the newest kid on the block and a much anticipated one. This is a new technology which can also potentially reduce the need of invasive tests.

The interest in En-Face OCT has resurfaced. Let's see at our meeting why this is. While long-term periodic anti-VEGF and steroid intravitreal injections are now the mainstays of our therapeutic armamentarium in the battle against Diabetic Macular Edema (DME), new imaging and laser technologies have the potential to more easily target the RPE while minimizing outer retinal injury and perhaps, at the same time, reduce the intravitreal injections required. Laser technology remains the "Gold Standard" for the treatment of focal DME and areas of non perfusion. It is therefore important to continue developing laser technology and for ourselves to keep up to date with new developments in this field.

The new format this year includes 10min presentations to allow for a variety of topics and speakers from Europe and elsewhere.

We have also included in this year's program a Hands-on Workshop that will allow you yourself to try the new technology presented.

This year, we have invited Gregoire Cosendai, PhD. as our Keynote Speaker to talk to us on a game-changing technology. Doctor Cosendai is Vice President - Europe of Second Sight Medical Products, the California-based company that has developed the first commercially available electronic retinal implant. This is a breakthrough technology that can restore visual function lost due to degenerative diseases of the outer retina. It is a great pleasure to welcome Greg to Nice to talk to us about not only about the latest clinical results and future plans but also the story behind the development of this technology.

Of course, we will also have time to continue our discussions and meet old and new friends over drinks and a buffet!

We look forward to sharing with you another exciting evening.

See you in Nice.

Prof. Paulo E. Stanga

Due to the popularity of this meeting, please RSVP.
Places will be allocated on a strictly First Come, First Serve basis.

Speakers for OCT session



Max Akiba, PhD (Japan)

Eye Care Technology Development Dept.,
Research & Development Div. TOPCON Corporation, Japan

Frontiers of swept-source OCT
- possibility from vitreous to scleral imaging -



Professor Francesco Bandello, MD (Italy)

Professor and Chairman Department of Ophthalmology,
Ospedale San Raffaele of Milan, Italy

En Face OCT; Clinical Indications and Findings



Professor Jose Maria Ruiz Moreno, MD (Spain)

Professor of Department of Ophthalmology,
Castilla La Mancha University, Albacete, Spain

Choroidal Imaging by "en face" SS-OCT:
Imaging and measurements



Professor Magdy Moussa, MD (Egypt)

Professor of Ophthalmology & vitreoretinal consultant,
Faculty of Medicine, Tanta University, Egypt

The importance of SS OCT in the Management of CSR



Professor Paulo Stanga, MD (UK)

Professor of Ophthalmology & Retinal Regeneration
University of Manchester

Angio-OCT; Clinical Indications and Findings

Speakers for PASCAL session



Professor Jan EE Keunen, MD (The Netherlands)

Professor of Ophthalmology,
Radboud University Medical Centre, Nijmegen, Netherlands

Don't undertreat in PRP using a pattern laser



Professor Pascale Massin, MD (France)

Professor of Ophthalmology,
Hôpital Lariboisière, Paris 7 University, France

Why the laser keeps its place in the treatment of
diabetic retinopathy at the time of intravitreal injections?

Speaker for Keynote lecture



Gregoire Cosendai, PhD (Switzerland)

Vice President - Europe Second Sight Medical Products
(Switzerland) Sarl

The Argus II electronic retinal implant: the story behind
its creation, latest results and future plans